BACKGROUND CONTEXT While joint arthroplasty literature has shown increased complication rates and costs for patients seropositive for HCV without liver disease compared to those without HCV, this comorbidity has not been explored in the spine literature. To our knowledge, this is the first publication in the lumbar spine literature to solely focus on HCV as the disease burden. PURPOSE To identify if HCV diagnosis influences in-hospital lengths of stay (LOS), postoperative complications, readmission rates or costs following primary posterior lumbar fusions in an elective setting. STUDY DESIGN/SETTING Retrospective review. PATIENT SAMPLE A national database was queried for patients who underwent primary lumbar spine fusion for degenerative lumbar pathology with Medicare insurance from 2005-2014. Patients with a diagnosis of degenerative lumbar disease were identified using ICD-9 diagnosis codes: 722.52. The database was subsequently queried for all patients with HCV using ICD-9 diagnosis codes: 070.51, 070.54, 070.71, and V02.62. A strict inclusion and exclusion criteria yielded a total cohort of 28,841 individuals undergoing primary lumbar fusion, which included 4,807 patients with HCV seropositivity, and 24,034 without HCV-positive status. Patients with HCV were designated as “HCV” and those without HCV were designated as “Controls.” OUTCOME MEASURES Primary outcomes analyzed in the study included: in-hospital LOS, readmission rates, medical complications and costs of care. Reimbursements were utilized as a proxy for cost, as used in previous studies. Medical complications analyzed included: myocardial infarction, cerebrovascular accidents, respiratory failure, pneumonia, paralytic ileus, urinary tract infections (UTIs), neurodegenerative complications, transfusion of blood products, dural tears and wound-/implant-related infections. METHODS A national database was queried for patients who underwent primary lumbar spine fusion for degenerative lumbar pathology with Medicare insurance from 2005-2014. The 90-day postoperative complication rates, readmission rates and treatment costs were queried. To limit confounding, HCV patients were matched with a control cohort of non-HCV patients using patient demographics, treatment modality, and comorbid conditions and then analyzed by multivariate logistic regression. Patients with active liver disease were excluded to better isolate HCV as the comorbidity. RESULTS A cohort of 28,841 patients was included in the final analysis. Postoperatively, compared to those without HCV infection, those with HCV had significantly higher odds of needing a blood transfusion (OR: 3.06), pneumonia (OR: 2.49), respiratory failure (OR: 2.49) UTIs (OR: 1.89), wound-/implant-related infections (OR: 1.74), cerebrovascular events (OR: 1.70), or any post-operative complication within 90 days (OR: 2.93; all p: CONCLUSIONS In patients undergoing primary lumbar fusion, a seropositivity for HCV without liver disease is associated with higher costs and complication rates, including higher rates of blood transfusion requirements and pneumonia-related complications. This data shed new light on elective spine surgery in HCV patients and may influence the risks and benefits considerations for surgeons considering lumbar fusion in this population. FDA DEVICE/DRUG STATUS This abstract does not discuss or include any applicable devices or drugs.